Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05621811 · ClinicalTrials.gov registry record · Phase 2

Different Doses of Naronapride Vs. Placebo in Gastroparesis

A Phase 2 study of Gastroparesis, sponsored by Dr. Falk Pharma.

Recruiting
Registry status
Phase 2
Development phase
320
Enrollment target
20
Study locations

NCT05621811 is a Phase 2 study of Gastroparesis that is actively recruiting participants, run by Dr. Falk Pharma. The registered enrollment target is 320 participants, roughly in line with the 295-participant average among 44 other Gastroparesis trials with a reported enrollment target. The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05621811, a Phase 2 study of Gastroparesis, is actively recruiting participants, sponsored by Dr. Falk Pharma.

RECRUITING
Registry status
Phase 2
Development phase
320 participants
Enrollment target
20
Study locations

Study Summary

This is a double-blind, randomized, multicenter, placebo-controlled, comparative phase II dose-finding trial. The trial will be conducted with four treatment groups in the form of a parallel group comparison and will serve to compare oral treatment with daily doses of 10, 20, or 40 mg Naronapride vs. placebo for the treatment of patients with Gastroparesis.

Conditions Studied

Gastroparesis

Interventions

  • DRUG Placebo
  • DRUG Naronapride

Study Locations (20)

Florida

  • Dr Falk Investigational Site - Clearwater
  • Dr Falk Investigational Site - Doral
  • Dr Falk Investigational Site - Hollywood
  • Dr Falk Investigational Site - Maitland
  • Dr Falk Investigational Site - Miami
  • Dr Falk Investigational Site - Miami
  • Dr Falk Investigational Site - Viera

California

  • Dr Falk Investigational Site - Chula Vista
  • Dr Falk Investigational Site - Lomita

Louisiana

  • Dr Falk Investigational Site - Houma
  • Dr Falk Investigational Site - Marrero

Michigan

  • Dr Falk Investigational Site - Flint
  • Dr Falk Investigational Site - Flint

Tennessee

  • Dr Falk Investigational Site - Cordova
  • Dr Falk Investigational Site - Nashville

Kansas

  • Dr Falk Investigational Site - Topeka

Kentucky

  • Dr Falk Investigational Site - Crestview Hills

New York

  • Dr Falk Investigational Site - New York

Trial Details

FieldValue
Enrollment Target 320 participants
Start Date 2023-01-03
Est. Completion 2025-12
Phase Phase 2

Sponsor

Dr. Falk Pharma

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05621811

The ClinicalTrials.gov registry entry for NCT05621811 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 295-participant average among 44 other Gastroparesis trials with a reported enrollment target. The listed sponsor is Dr. Falk Pharma, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Gastroparesis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05621811 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, Louisiana.

Frequently Asked Questions

What is clinical trial NCT05621811 about?

NCT05621811 is a clinical study titled "Different Doses of Naronapride Vs. Placebo in Gastroparesis". This is a double-blind, randomized, multicenter, placebo-controlled, comparative phase II dose-finding trial. The trial will be conducted with four treatment groups in the form of a parallel group comparison and will serve to compare oral treatment with daily doses of 10, 20, or 40 mg Naronapride vs...

What is the current status of trial NCT05621811?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 320 participants. The study started on 2023-01-03. Estimated completion is 2025-12.

What conditions does trial NCT05621811 study?

This clinical trial studies the following conditions: Gastroparesis.

What interventions are being tested in trial NCT05621811?

The interventions under investigation include: Placebo (DRUG), Naronapride (DRUG).

Who is sponsoring clinical trial NCT05621811?

This trial is sponsored by Dr. Falk Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05621811 being conducted?

This trial has 20 study locations across California, Florida, Kansas, Kentucky, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastroparesis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Gastroparesis

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.